Search results for "From ACP Internist Weekly"
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/12/09/7.htm
9 Dec 2022
Nocturnal hypoglycemia underdiagnosed in older patients on insulin for type 2 diabetes
An industry-funded study of patients age 75 years and older who were taking insulin for type 2 diabetes found that almost two-thirds (65.2%) experienced nocturnal hypoglycemia during a 28-day study period.
https://diabetes.acponline.org/archives/2023/04/14/6.htm
14 Apr 2023
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/11/11/6.htm
11 Nov 2022
Almost 4 in 10 with type 1 diabetes were diagnosed in adulthood
Peak diagnosis age was approximately 15 years, and the median age of diagnosis was 24 years, but 37% of adults with type 1 diabetes reported having been diagnosed after age 30 years in a recent study.
https://diabetes.acponline.org/archives/2023/10/13/9.htm
13 Oct 2023
Nonsugar sweeteners should not be used for weight loss, WHO guideline states
The World Health Organization (WHO) cited a lack of evidence suggesting that short-term use of nonsugar sweeteners affected body weight or other measures of adiposity, as well as possible long-term undesirable effects on noncommunicable diseases and death.
https://diabetes.acponline.org/archives/2023/06/09/7.htm
9 Jun 2023
ADA, EASD update guidance on managing hyperglycemia
An updated consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) addressed social drivers of health, lifestyle modifications, and new drug classes for type 2 diabetes.
https://diabetes.acponline.org/archives/2022/10/14/7.htm
14 Oct 2022
Overweight, obesity poorly managed in type 1 diabetes
While U.S. adults with type 1 diabetes have rates of overweight and obesity virtually identical to those in the general adult population, only about 50% received lifestyle recommendations for weight management from clinicians or tried lifestyle modifications.
https://diabetes.acponline.org/archives/2023/03/10/9.htm
10 Mar 2023
Large review compares benefits, harms of drugs to treat type 2 diabetes
High-certainty evidence indicated that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists reduce all-cause death, while finerenone probably also reduced mortality based on moderate-certainty evidence.
https://diabetes.acponline.org/archives/2023/05/12/6.htm
12 May 2023
Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find
A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
https://diabetes.acponline.org/archives/2022/10/14/8.htm
14 Oct 2022
Higher aspirin dose no more effective for CV prevention in high-risk patients with diabetes
A subgroup analysis of a randomized trial found that patients with diabetes and atherosclerotic cardiovascular (CV) disease had similar outcomes whether they took 81 mg or 325 mg of aspirin daily.
https://diabetes.acponline.org/archives/2023/10/13/10.htm
13 Oct 2023